Therapeutic effect of type II collagen allosteric peptide for treating rheumatoid arthritis

An allosteric peptide, rheumatoid technology, applied in medical preparations containing active ingredients, anti-inflammatory agents, peptide/protein components, etc., can solve problems such as many side effects, inability to inhibit rheumatoid arthritis, and inability of patients to take medication

Inactive Publication Date: 2006-11-29
PEOPLES HOSPITAL PEKING UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These drugs do not act on the initial link in the treatment of rheumatoid arthritis, and cannot inhibit rheumatoid arthritis at the earliest stage of onset
Moreover, due to the extensive immunosuppressive effect of these drugs, there are many side effects, so many patients cannot take drugs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic effect of type II collagen allosteric peptide for treating rheumatoid arthritis
  • Therapeutic effect of type II collagen allosteric peptide for treating rheumatoid arthritis
  • Therapeutic effect of type II collagen allosteric peptide for treating rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Embodiment 1: the synthesis of polypeptide

[0021] The amino acids (267Q and 270K) recognized by the TCR in the CII263-272 polypeptide were replaced with the A of the short side chain, thereby obtaining three CII263-272 allosteric peptides (altered peptide ligand, APL). See Table 1 for their sequences. Simultaneously, type II collagen 263-272 (FKGEQGPKGE) prototype peptide was synthesized. The above polypeptides were all synthesized by Shanghai Boya Company by solid-phase synthesis and purified by high-performance liquid chromatography. In order to facilitate the transport of the peptide into the cell, the amino terminus of the peptide is connected with myristic acid. The results of mass spectrometry showed that the sequence of the polypeptide was correct and the purity was over 95%.

[0022] Peptide name

peptide sequence

CII263-272

APL1

APL2

APL3

Ma

---

---

---

F

---

---

---

...

Embodiment 2

[0025] Implementation 2: In silico simulation of the binding of CII263-272 prototype and allosteric peptides to HLA-DR4 molecules

[0026] Using the Red Hat Linux 9 operating system, using the HLA-DR4-CII1168-1179 crystal structure (PDB: 2SEB) as a template, the prototype of CII263-272 and allosteric peptides were tested on a CPU 2.4 GHz Xeon CPU×2 workstation and rheumatoid arthritis. Computer simulation experiment of HLA-DR4 molecular binding of the sensitive gene. The binding ability of each polypeptide to HLA-DR4 molecules was evaluated by SCORE scoring software. The size of the binding ability is expressed by pKd value (the negative logarithm of the dissociation constant Kd). The larger the pKd value, the stronger the intermolecular binding force.

[0027] The results show that the CII263-272 prototype peptide molecule can be well embedded in the antigen-binding groove of HLA-DR4, while the long side chains of 267Q and 270K protrude out of the antigen-binding groove, fo...

Embodiment 3

[0028] Example 3: Hyporesponsiveness of type II collagen allosteric peptides in peripheral blood T cells of RA patients with low or no T cell reactivity.

[0029] In an embodiment of the present invention, the reactivity of peripheral blood T cells of RA patients to three CII263-272 allosteric peptides was studied, and the production levels of Th1 type cytokines IL-2 and IFN-γ under the stimulation of allosteric peptides were detected. Variety.

[0030] Peripheral blood mononuclear cells (PBMCs) from RA patients were isolated by density gradient centrifugation and seeded in 96-well plates (2×10 5CII263-272 prototype peptide or three allosteric peptides (10 μg / ml) were added respectively, the positive control was phytohemagglutinin (10 μg / ml), and the negative control was 1640 culture solution. Make 3 replicate wells for each group, at 37°C, 5% CO 2 Cultivate under conditions for 5 days, add 1 μCi to each well 8 hours before the end of the culture 3 H-labeled thymidine ( 3 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An application of the collagen II (CII) allosteric peptide in treating rheumatoid arthritis (RA) by specifically suppress the exception immunoreaction of RA in upstream path is disclosed.

Description

[0001] This study involves the preparation of type II collagen (CII) allosteric peptide and its drug application in rheumatoid arthritis (RA) and other autoimmune diseases. 1. Background Technology [0002] Rheumatoid arthritis is a systemic autoimmune disease characterized by chronic progressive joint disease. Lesions mainly involve multiple joints in the whole body, showing multiple and symmetrical chronic synovitis, which in turn causes cartilage and bone destruction, and severe cases can lead to joint deformities and even disability. In my country, the prevalence rate of rheumatoid arthritis is 0.32%-0.38%, the total number of patients exceeds 4 million, and the disability rate is as high as 93%. It is one of the main diseases that cause labor force loss and disability. [0003] Recent studies on the pathogenesis of rheumatoid arthritis have shown that autoantigen-driven T cell activation is the basis for the pathogenesis and evolution of rheumatoid arthritis. Antigen pep...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/39A61P29/00A61P19/02
Inventor 栗占国
Owner PEOPLES HOSPITAL PEKING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap